Background: Neurofilament light chain (NFL) is a cerebrospinal fluid (CSF) marker of neuroaxonal damage in multiple sclerosis (MS). Objective: To determine the correlation of NFL in CSF and serum/plasma, and in plasma after switching from injectable MS therapies to fingolimod. Methods: A first cohort consisted of MS patients (n = 39) and neurological disease controls (n = 27) where CSF and plasma/serum had been collected for diagnostic purposes. A second cohort (n = 243) consisted of patients from a post-marketing study of fingolimod. NFL was determined with Single Molecule Array (Simoa™) technology (detection threshold 1.95 pg/mL). Results: Mean NFL pg/mL (standard deviation (SD)) was 341 (267) and 1475 (2358) in CSF and 8.2 (3.58) and 17.0 (16.94) in serum from controls and MS, respectively. CSF/serum and plasma/serum levels were highly correlated (n = 66, rho = 0.672, p < 0.0001 and n = 16, rho = 0.684, p = 0.009, respectively). In patients starting fingolimod (n = 243), mean NFL pg/mL (SD) in plasma was reduced between baseline (20.4 (10.7)) and at 12 months (13.5 (7.3), p < 3 × 10 −6 ), and levels remained stable at 24 months (13.2 (6.2)). Conclusion: NFL in serum and CSF are highly correlated and plasma NFL levels decrease after switching to highly effective MS therapy. Blood NFL measurement can be considered as a biomarker for MS therapy response.
Introduction
An increasing body of evidence supports the use of markers for inflammatory activity for assessing disease activity in multiple sclerosis (MS) patients, in turn of relevance for treatment decisions. To date, only magnetic resonance imaging (MRI) is available in clinical practice and has shown a high correlation to relapse rates in meta-analyses of several large trials. 1 Still, it is not established how well clinically available MRI measures (new T1/T2 and contrast-enhancing lesions) correlate with neuroaxonal damage, in turn a major determinant of permanent disability in MS, see, for example, Tallantyre et al. 2 In addition, repeated MRI examinations for monitoring purposes are usually restricted to the brain and therefore do not reflect pathology of the spinal cord. 3 The number of candidate biomarkers of possible value in MS is very large. 4 However, in most cases, relation to important disease processes, such as neuroaxonal damage, or prognostic value for important outcomes, such as long-term disability, is lacking. Among different markers for neuroaxonal damage, neurofilaments, and especially neurofilament light chain (NFL), has emerged as promising candidates. [5] [6] [7] Furthermore, several studies have used cerebrospinal fluid (CSF) NFL as a marker for therapeutic responses. [8] [9] [10] [11] [12] [13] We have previously shown that CSF NFL levels correlate with several biomarkers of intrathecal inflammation and that both CSF NFL and inflammatory markers decrease with age in MS. 14 Still, an important obstacle for a wider introduction into clinical practice is the requirement of CSF sampling by lumbar puncture. Disanto et al. 15 have reported serum NFL levels in patients with a clinically isolated syndrome (CIS) using an electrochemiluminescence (ECL)-based method. Serum NFL levels were about threefold higher in CIS patients compared to healthy controls, and within the CIS group NFL correlated with MRI activity and higher disability scores at CIS presentation. Additional studies from the same group have further shown correlations of serum NFL levels with MRI data in two smaller cohorts of early MS patients. 16, 17 Although more sensitive than ordinary enzyme-linked immunosorbent assay (ELISA), the ECL-based method has a reported analytical sensitivity limit above that normally seen in healthy controls and also with a significant overlap with levels seen in MS patients. 18 However, we recently developed an ultrasensitive assay for serum NFL using Single Molecule Array (Simoa™) technology, 19 which represents a novel immune-based ultrasensitive protein detection method that has a 25-fold improved analytical sensitivity as compared to the ECL-based method and shows correlations between serum and CSF levels throughout the span of normal to pathological concentrations. 20 We here sought to replicate this finding in a cohort of MS patients and controls and also determined plasma NFL levels in a large realworld cohort of MS patients switching from injectable therapies to fingolimod.
Materials and methods

Patients and samples
Two different patient cohorts were used in the study. The first cohort (Cohort 1; n = 66) consisted of patients attending the Department of Neurology at the Karolinska University Hospital for MS or psychiatric or other neurological conditions where sampling of blood and CSF for diagnostic purposes had been undertaken. The controls consisted of non-inflammatory neurological disease controls (NINDC) (n = 27) patients (56% women; mean age, 35.2 years; range, 20-56) without signs of intrathecal inflammation on standard CSF tests ( Table 1) . The group comprised the following diagnoses: new onset psychotic symptoms (n = 11), sensory symptoms/paresthesia (n = 10), fatigue (n = 1), dizziness (n = 1), headache (n = 2), and visual disturbance (n = 2). The MS group consisted of 39 patients (54% women; mean age, 39.6 years; range, 23-70), with the following disease courses: relapsing-remitting multiple sclerosis (RRMS) in remission (n = 29), RRMS with clinical relapse symptoms within 3 months of sampling (n = 4), secondary progressive multiple sclerosis (SPMS; n = 3), primary progressive multiple sclerosis (PPMS; n = 3). CSF and plasma/serum were collected at the same time point using standardized protocols. CSF was centrifuged immediately and the supernatant was frozen at −80°C within 1 hour.
The second cohort (Cohort 2) consisted of patients enrolled in a post-marketing study of fingolimod (Gilenya®). All clinics in Sweden starting patients on newer MS disease modulatory treatments (DMTs) participate in the Immunomodulation and Multiple Sclerosis Epidemiology (IMSE) study. As of 31 March 2016, a total of 1467 patients had been recruited to the study. All patients are followed over time using the nationwide web-based Swedish Neuroregistry (NeuroReg) and donate a plasma sample at baseline and at 12 and 24 months after treatment initiation. Samples are sent by surface mail in room temperature to a centralized biobanking unit at Karolinska Institutet. From this cohort (n = 261), individuals were selected based on availability of a baseline sample and at least one sample at either 12 or 24 months, as well as information on prior treatment. We limited the analysis to patients with RRMS at baseline, who had not made treatment breaks for more than 2 weeks, and those which had successful NFL measurements for at least two time points resulting in 243 included patients. Thus, n = 241 had samples from baseline and 12 months, n = 119 from baseline and 24 months, and n = 119 from baseline, 12, and 24 months (Table 2 ). In all, 24% had switched from glatiramer acetate and 75% from interferons. The remaining 1% had either not been treated for MS previously or had been treated with study drug or pulsed corticosteroids. The stated reasons for switching from injectable therapies were lack of effect (74%), side effects (15%), other reasons (8%), and anti-drug antibodies (3%).
All patients provided written consent and the study was approved by the Regional Ethics Committee of Stockholm (2009/2107-31/2 and 2011/641-31/4, respectively).
Determination of NFL using Simoa
CSF NFL levels were determined using the NF Light kit from UmanDiagnostics (Umeå, Sweden) according to the manufacturer's instructions. Samples were run in duplicate with an intra-assay variability of 3.5% and a lower detection threshold of 32 pg/mL. Plasma NFL levels were determined using the same NFL antibodies from UmanDiagnostics, transferred onto the Simoa platform using a homebrew kit (Quanterix Corp, Boston, MA, USA). The lower limit of quantification (LLoQ), determined by the blank mean signal + 10 standard deviation (SD), was 1.95 pg/ mL. All samples measured were above LLoQ in a pilot run on plasma from 100 patients and controls, where a range from 2.2 to 403 pg/mL could be demonstrated. In the subsequent analysis, all samples were run in one batch. The analyses were performed by a board-certified laboratory technician using one batch of reagents with intra-assay coefficients of variation below 10%. However, for quality control samples with a concentration of 14.2 and 141.4 pg/mL, respectively, inter-assay repeatability was 9.8% and 9.4%. The NFL concentrations from three plasma samples from one patient were below LLoQ; they were excluded from the analysis. 
Results
Correlation between NFL levels in CSF and serum/plasma
We first determined NFL levels in CSF and serum in a heterogeneous group of patients with MS and NINDC (Cohort 1). The mean NFL level in CSF was 341 (SD = 267) and 1475 (SD = 2358) pg/mL in controls and MS, respectively. In the MS cohort, the highest mean NFL levels were found in RRMS patients with a recent relapse (3840 pg/mL), whereas mean levels were lower in RRMS patients in remission (1343 pg/mL) and SP/PPMS patients (535 pg/ mL). There was no significant correlation between serum or CSF NFL levels and the albumin quotient, IgG index, or CSF cell count neither in MS patients nor NINDC (data not shown). Subsequently, using the same antibodies transferred onto the Simoa platform, NFL levels were determined in paired serum samples. At the group level, mean NFL levels were 8.2 (SD = 3.58) and 17.0 (SD = 16.94) pg/mL in controls and MS (p = 0.0005), respectively. The levels of NFL in paired CSF and serum samples were highly correlated (rho = 0.672, p < 0.0001) (Figure 1(a) ). As a subsequent step, we also tested the degree of correlation between paired serum and plasma samples in a subpopulation (n = 16) of patients from Cohort 1, again demonstrating a high degree of correlation (rho = 0.684, p = 0.009) (Figure 1(b) ).
NFL levels in patients switching to fingolimod
Next, we determined NFL levels in samples collected in context of a large nationwide post-marketing study for fingolimod (Cohort 2). The samples were selected based on the availability of a baseline sample and at least one follow-up sample as well as information on prior treatment with injectable therapies (interferons, glatiramer acetate), and was limited to patients with RRMS at treatment start, but were otherwise randomly chosen. Cohort 2 consisted of 243 individuals and a total of 603 samples ( Table 2) .
As a sensitivity analysis, given that samples had been sent by surface mail with a variable time in the post, we calculated mean NFL levels in relation to number of days between sampling and arrival, which showed that the time (range from 1 to 7 days) the sample had been in the post did not affect the mean level (rho = 0.046, p = 0.60) (Figure 2 ). Therefore, we did not correct for this in the subsequent analyses. In addition, re-testing to exclude batch effects revealed an excellent reproducibility (data not shown).
At the group level, mean plasma NFL measured at baseline, 12, and 24 months after start of fingolimod therapy demonstrated a significant 34% reduction at 12 months (13.5 pg/mL, SD = 7.34) compared to baseline (20.4 pg/mL, SD = 17.79), where levels remained similar at 24 months (13.20 pg/mL, SD = 6.19) compared to 12 months (Table 2 ; Figure  3 (a)). The reduction in NFL was associated with a reduced Multiple Sclerosis Severity Score (MSSS) from a median of 2.30 at start of therapy, 2.00 at 12 months, and 1.70 at 24 months. While most subjects (n = 191) demonstrated lowered levels, a minority (n = 49) displayed increased NFL levels after start of fingolimod, see below.
Sub-group analyses
Sex did not affect NFL levels at baseline, but males had a tendency for lower levels than females at both 12 and 24 months (p = 0.09 and p = 0.16, respectively). Age was positively correlated with NFL levels at all time points: baseline (rho = 0.216, p < 0.0008), 12 months (rho = 0.306, p < 2 × 10 −6 ) ( Figure 3(b) ), and 24 months (rho = 0.221, p < 0.02). MSSS was positively correlated with NFL levels at baseline (rho = 0.19, p < 0.03), with a tendency for correlation at 12 months (rho = 0.14, p = 0.109), but not at 24 months (rho = 0.10, p = ns). Furthermore, there was a weak, non-significant trend for higher baseline NFL levels in patients switching to fingolimod due to neutralizing antibodies to interferon or lack of effect compared with those switching due to side effects or other reasons (p = 0.24).
In the univariate analysis, baseline NFL was associated with age at sampling (p = 0.031) and Expanded Disability Status Scale (EDSS) at baseline (p = 0.032), with a tendency for association with number of relapses before treatment start (p = 0.097) (supplementary Table 1 ). In the multivariate analysis, only number of relapses the year before start of fingolimod was significantly associated with higher baseline NFL (p = 0.04). Change in NFL levels from baseline to 12 months was highly associated with the baseline NFL level both in the univariate and multivariate model (p < 2 × 10 −16 ), which was also the case for number of relapses the year before start of fingolimod (p = 0.0035 and p = 0.017, respectively) (supplementary Table 2 ). Male sex tended to be associated with a greater reduction in NFL (univariate p = 0.092; multivariate p = 0.17). In all, 49 patients displayed increasing NFL levels after switching to fingolimod compared to 191 patients with reduced levels. A comparison between these two groups showed that patients with increased NFL levels on fingolimod had a lower starting NFL concentration and that they were older, had a higher age at disease onset, and had fewer relapses before switching to fingolimod (Table 3) .
Discussion
We determined NFL levels in paired CSF and serum samples in patients with MS and controls, as well as in a large cohort of patients with MS switching from first-generation immunomodulatory therapies to fingolimod, where we provide preliminary evidence for the usefulness of NFL levels in blood as a biomarker to assess disease activity and therapeutic efficacy in MS. Thus, in a large group of MS patients switching mainly from interferons or glatiramer acetate to fingolimod, a highly significant drop in plasma NFL levels had occurred by 12 months and was retained at 24 months. All samples were collected in context of a nationwide post-marketing study, which means that measurements represent a large real-world population with population-based sampling. However, weaknesses include incomplete information on some of the clinical variables, especially EDSS and relapses, and lack of MRI data, which limit the possibilities of correlation with clinical and brain imaging outcome variables.
Currently, there are no validated fluid biomarkers for disease activity in MS that could function as a complement to MRI. 4 Even if MRI measures are correlated with clinical disease status, standard measures for assessing focal active inflammation mainly in the brain white matter are through identifying contrastenhancing or newly appearing T2 lesions, which only reflect certain aspects of the MS disease processes. Thus, there is a growing body of evidence from pathological studies that MS comprise also diffuse axonal injuries occurring independent of lesions, as well as gray matter pathology. 21, 22 Volumetric MRI techniques can show combined effects of focal and diffuse injuries, but will likely be insensitive for changes over shorter time periods, at least at the individual level.
Since it is well established that degree of neurodegeneration is the most important determinant of longterm disability in MS, see, for example, Tallantyre et al., 2 it would prove useful to identify biomarkers to assess the rate of ongoing neurodegeneration. Among such markers, the evidence base for CSF NFL is the strongest, including its usefulness as a marker for therapeutic response. [8] [9] [10] [11] [12] [13] Interestingly, blood NFL levels were recently shown to accurately detect the onset of neurodegeneration in transgenic animal models of neurodegenerative diseases, and in the same study, elevated blood NFL levels were demonstrated in the human diseases they model. 23 In order to have a more widespread clinical use of neurofilament in MS, the assay will have to be developed for measuring levels in blood. Until recently, this has not been possible, since the sensitivity of most assays have been well above of what is seen in healthy controls, which also is the treatment target for patients with MS. However, promising preliminary results have been demonstrated with the Simoa platform, where the analytical sensitivity is well below that of neurofilament levels seen in healthy controls. 20 Increased serum or plasma NFL concentrations measured with Simoa further reflect neuroaxonal injury in human neurodegenerative diseases such as atypical parkinsonian disorders, 24, 25 frontotemporal dementia, 26 Alzheimer's disease, 27 and HIV-associated neurocognitive dysfunction, 19 as well as in traumatic brain injury. 28 Collectively, these findings suggest that blood NFL can be used as a biomarker to assess disease activity and therapeutic efficacy in MS. In this context, our findings are important as they represent a proof-of-principle of the feasibility of testing in a routine clinical context.
This also opens interesting perspectives that comprise the possibility to re-analyze archival blood samples from clinical trials, sometimes with several years of follow-up after the double blinded period, which can be used to generate important information on how well this biomarker can predict long-term clinical outcomes, and conversely, to assess drug effects on neurodegeneration. Still, some caution is warranted with regard to the validity of blood NFL measurements to assess inflammatory disease activity at the individual level. Thus, the dynamic range of blood NFL levels is compressed compared to measurements in CSF and might also be affected by individual variability in blood-brain barrier (BBB) function. For example, it is not known if sampling during a low grade inflammation or infection might affect the leakage of neurofilament over the BBB and thus result in falsely elevated levels in the peripheral compartment. Therefore, repeated measures over longer periods of time might be needed to more accurately assess individual NFL levels. On the other hand, MRI measurements as outcome measures are less quantitative than fluid biomarkers and largely reflect focal breakdown of the BBB with variable degrees of myelin loss and axonal injury. 29 We also found that NFL levels on fingolimod treatment correlate with age, which replicate previous findings from CSF NFL measurements in healthy controls, 30 which suggest that adjustment for age might be needed.
In conclusion, we demonstrate a high degree of correlation between serum and CSF levels of NFL in patients with MS and controls. Furthermore, we show that in patients switching from injectable MS therapies, the plasma NFL levels are reduced. Additional studies are needed to demonstrate correlation between blood NFL levels and long-term clinical outcomes. 
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